FCMI
ABUS icon

Foresite Capital Management IV’s Arbutus Biopharma ABUS Stock Holding History

Foresite Capital Management IV’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,332,616
Closed -$10.4M – 14
2020
Q3 		$10.4M Buy
+3,332,616
New +$10.1M 2.35% 11
2020
Q1 		– Sell
-3,705,128
Closed -$10.3M – 12
2019
Q4 		$10.3M Buy
+3,705,128
New +$5.99M 4.44% 8
2019
Q3 		– Sell
-608,151
Closed -$1.26M – 20
2019
Q2 		$1.26M Sell
608,151
-196,295
-24% -$502K 0.36% 21
2019
Q1 		$2.88M Sell
804,446
-777,829
-49% -$2.99M 1.04% 15
2018
Q4 		$6.06M Sell
1,582,275
-1,094,550
-41% -$5.39M 2.78% 12
2018
Q3 		$25.3M Buy
2,676,825
+25,000
+0.9% +$248K 8.29% 5
2018
Q2 		$19.4M Buy
2,651,825
+1,166,580
+79% +$6.94M 6.6% 8
2018
Q1 		$7.43M Buy
1,485,245
+1,334,653
+886% +$7.07M 3.08% 13
2017
Q4 		$760K Buy
+150,592
New +$883K 0.53% 13

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Foresite Capital Management IV's ABUS Position: Q4 2020 in Review

Foresite Capital Management IV sold out of Arbutus Biopharma (ABUS) in Q4 2020, closing a stake of 3,332,616 shares — an estimated $10.4M sold.

Foresite Capital Management IV first reported a position in ABUS in Q4 2017 and held it in 9 quarters. The position peaked at $25.3M in Q3 2018. 80 funds tracked by Wall St. Rank hold ABUS as of Q4 2020.

  • Foresite Capital Management IV reported no remaining Arbutus Biopharma position as of Q4 2020 after selling out during the quarter.
  • Foresite Capital Management IV sold 3,332,616 Arbutus Biopharma shares in Q4 2020, an estimated $10.4M.
  • Foresite Capital Management IV first reported a position in Arbutus Biopharma in Q4 2017 and held it in 9 quarters.
  • Foresite Capital Management IV's Arbutus Biopharma position peaked at $25.3M in Q3 2018.
  • 80 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2020.

Based on Foresite Capital Management IV's 13F filing for Q4 2020, filed 16 Feb 2021.